VIPomas Treatment & Management
- Author: Sai-Ching Jim Yeung, MD, PhD, FACP; Chief Editor: George T Griffing, MD more...
Initial treatment of VIPomas is directed toward correcting volume and electrolyte abnormalities. Octreotide acetate controls diarrhea in up to 90% of patients with VIPomas. Glucocorticoids reduce symptoms in 50%.
Systemic chemotherapy may be needed in cases of unresectable or progressive disease. Streptozocin, doxorubicin, fluorouracil, or a combination of these appears to be beneficial, though the number of treated cases has been limited.
Local tumor resection is the treatment of choice. In advanced disease, tumor debulking may relieve symptoms, but it is not effective in all cases. Embolization of the hepatic artery with doxorubicin HCl and ethiodized oil may provide palliation in patients with extensive hepatic disease. This treatment may be repeated several times, depending on tumor growth and symptoms. External radiation therapy may be indicated in unresectable tumors. Laparoscopic surgical resection has been successful in at least one adult with hepatic metastasis.
In patients with VIPoma, parathyroidectomy does not correct hypercalcemia. (VIP and its parathyroid hormone–like action cause hypercalcemia.)
Initial treatment for VIPoma is aimed at correcting any volume, electrolyte, and acid-base abnormalities with intravenous (IV) normal saline, potassium chloride, and, if acidosis is severe, sodium bicarbonate. In many cases, these abnormalities are pronounced enough to necessitate hospital admission.
In more than 90% of patients, somatostatin effectively reduces serum vasoactive intestinal peptide (VIP) levels and promptly controls diarrhea. To circumvent the short serum half-life of somatostatin, the derivative octreotide is used. A long-acting octreotide formulation is available that allows once-monthly intragluteal administration. (Patients may have to make monthly clinic visits to receive the injections.) Diarrhea recurs when treatment is discontinued. It is currently debated whether somatostatin analogues also diminish tumor size.
Unless a surgical cure has been achieved (see Surgical Intervention), octreotide dosing is continued in most patients. Long-term octreotide treatment frequently results in gradually increasing resistance to this therapy. When the highest tolerable dosages of octreotide are unable to control symptoms, interferon alfa may be added to control diarrhea (and, possibly, achieve a modest reduction in tumor size).
Glucocorticoids are less effective, reducing symptoms in approximately 50% of patients. However, they are also less expensive.
In patients with advanced disease, tumors may respond to treatment with streptozocin-based chemotherapy (eg, streptozocin combined with 5-fluorouracil [5-FU]). If conventional chemotherapy and somatostatin are not effective, 5-FU may be combined with interferon alfa. Other chemotherapy agents that may be considered include dacarbazine and doxorubicin HCl.
The use of radiolabeled octreotide to target radiation treatment toward a VIPoma is based on the affinity of octreotide for the somatostatin receptors on the VIPoma cells. In one trial, half of the patients achieved stabilization of previously progressive tumors, with minimal bone marrow toxicity. This therapeutic approach may be applied to advanced neuroendocrine tumors in general.
Occasionally, external radiation therapy may be indicated for locally advanced unresectable tumors; however, experience with this treatment is limited.
Surgical exploration with tumor resection (see the image below) leads to cure in 50% of patients. After appropriate fluid and electrolyte replacement, all operable patients with apparently resectable disease should receive abdominal exploration with careful staging. Intraoperative ultrasonography of the pancreas may aid in locating an otherwise unidentified tumor. For patients without nodal or distant metastasis, complete surgical resection offers the only chance for a cure.
Local tumor resection is the treatment of choice.[14, 21, 22, 23] Pancreatoduodenectomy is indicated when the tumor is in the pancreatic head or processus uncinatus. If no tumor is found at surgery, a blind pancreatic tail resection may be performed. A total pancreatectomy no longer is recommended. Serum VIP levels may normalize within an hour after curative tumor resection. Preoperative treatment with a proton pump inhibitor is advisable to prevent rebound gastric acid hypersecretion after surgical tumor removal.
Severe hypotension may develop temporarily during and after tumor removal as a consequence of the vasodilatory effect of the VIP released during manipulation of the tumor. Severe hypertension may develop temporarily after tumor removal. Postoperatively, octreotide therapy will usually be needed indefinitely to control symptoms of VIP hypersecretion from residual tumor.
In most cases, at the time of diagnosis of VIPoma, metastatic disease is already present. For these patients, tumor debulking may reduce clinical symptoms,[14, 23] but for substantial clinical benefit to be achieved, operative planning ought to include resection of more than 90% of tumor volume.
Unresectable liver metastases may be treated with hepatic artery radioembolization or transcatheter chemoembolization with doxorubicin or cisplatin. When embolization is unsuccessful or not feasible for liver metastases, percutaneous or intraoperative radiofrequency tumor ablation may be attempted, though it is not ideal for large metastatic tumors.
All patients being surgically treated for a VIPoma should undergo a cholecystectomy to alleviate concerns of gallstones with somatostatin analogue therapy, in case such therapy is needed in the future. In patients with VIPomas, a parathyroidectomy does not correct hypercalcemia unless the VIPoma is resected.
Consultations with the following specialists may be warranted:
Endocrinologist - Consultation with an endocrinologist is indicated, particularly in MEN 1 or other polyhormonal secretion states or in cases where long-term hormonal suppression is required
Gastroenterologist - Consultation with a gastroenterologist may be indicated for evaluation of long-term diarrhea or for colonoscopic evaluation for villous adenoma
Surgeon - Consultation with a surgeon experienced in pancreatic surgery may be indicated if the evaluation suggests a resectable or debulkable tumor or if exploratory surgery is contemplated
Patients with VIPomas need frequent outpatient follow-up to monitor hydration status and serum electrolyte levels. In patients with continuing fluid loss that is not controlled effectively by medical and surgical treatment options, a long-term central venous access device may be implanted; the patient may be trained to replace fluid and electrolytes at home or in an ambulatory setting.
Posttreatment VIP levels may serve as a tumor marker for recurrent disease.
Batcher E, Madaj P, Gianoukakis AG. Pancreatic neuroendocrine tumors. Endocr Res. 2011. 36(1):35-43. [Medline].
Alvite-Canosa M, Alonso-Fernández L, Seoane-López M, Pérz-Grobas J, Berdeal-Díaz M, Carral-Freire M, et al. Benign pancreatic vipoma. Rev Esp Enferm Dig. 2011 Mar. 103(4):224-5. [Medline].
Strosberg JR, Cheema A, Weber J, Han G, Coppola D, Kvols LK. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol. 2011 Aug 1. 29(22):3044-9. [Medline].
Verner JV, Morrison AB. Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med. 1958 Sep. 25(3):374-80. [Medline].
Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science. 1970 Sep 18. 169(951):1217-8. [Medline].
Doherty GM. Rare endocrine tumours of the GI tract. Best Pract Res Clin Gastroenterol. 2005 Oct. 19(5):807-17. [Medline].
Ayub A, Zafar M, Abdulkareem A, et al. Primary hepatic vipoma. Am J Gastroenterol. 1993 Jun. 88(6):958-61. [Medline].
Aton SJ, Colwell CS, Harmar AJ, et al. Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons. Nat Neurosci. 2005 Apr. 8(4):476-83. [Medline]. [Full Text].
Rescorla FJ, Vane DW, Fitzgerald JF, West KW, Grosfeld JL. Vasoactive intestinal polypeptide-secreting ganglioneuromatosis affecting the entire colon and rectum. J Pediatr Surg. 1988 Jul. 23(7):635-7. [Medline].
Quak SH, Prabhakaran K, Kwok R, O'Reilly AP. Vasoactive intestinal peptide secreting tumours in children: a case report with literature review. Aust Paediatr J. 1988 Feb. 24(1):55-8. [Medline].
Müller S, Kupka S, Königsrainer I, Northoff H, Sotlar K, Bock T. MSH2 and CXCR4 involvement in malignant VIPoma. World J Surg Oncol. 2012. 10:264. [Medline].
Grier JF. WDHA (watery diarrhea, hypokalemia, achlorhydria) syndrome: clinical features, diagnosis, and treatment. South Med J. 1995 Jan. 88(1):22-4. [Medline].
Peng SY, Li JT, Liu YB, Fang HQ, Wu YL, Peng CH, et al. Diagnosis and treatment of VIPoma in China: (case report and 31 cases review) diagnosis and treatment of VIPoma. Pancreas. 2004 Jan. 28(1):93-7. [Medline].
Cesani F, Ernst R, Walser E, Villanueva-Meyer J. Tc-99m sestamibi imaging of a pancreatic VIPoma and parathyroid adenoma in a patient with multiple type I endocrine neoplasia. Clin Nucl Med. 1994 Jun. 19(6):532-4. [Medline].
de Herder WW. Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007 Mar. 21(1):33-41. [Medline].
Sofka CM, Semelka RC, Marcos HB, Woosley JT. MR imaging of metastatic pancreatic VIPoma. Magn Reson Imaging. 1997. 15(10):1205-8. [Medline].
Schillaci O, Corleto VD, Annibale B, Scopinaro F, Delle Fave G. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours. Ital J Gastroenterol Hepatol. 1999 Oct. 31 Suppl 2:S186-9. [Medline].
Virgolini I, Patri P, Novotny C, et al. Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol. 2001. 12 Suppl 2:S41-5. [Medline].
Khasraw M, Gill A, Harrington T, Pavlakis N, Modlin I. Management of advanced neuroendocrine tumors with hepatic metastasis. J Clin Gastroenterol. 2009 Oct. 43(9):838-47. [Medline].
Ruiz-Tovar J, Priego P, Martínez-Molina E, Morales V, Sanjuanbenito A, Lobo E. Pancreatic neuroendocrine tumours. Clin Transl Oncol. 2008 Aug. 10(8):493-7. [Medline].
Ghaferi AA, Chojnacki KA, Long WD, Cameron JL, Yeo CJ. Pancreatic VIPomas: subject review and one institutional experience. J Gastrointest Surg. 2008 Feb. 12(2):382-93. [Medline].
Akerström G, Hellman P. Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007 Mar. 21(1):87-109. [Medline].
King J, Quinn R, Glenn DM, Janssen J, Tong D, Liaw W, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008 Sep 1. 113(5):921-9. [Medline].
Bramley PN, Lodge JP, Losowsky MS, Giles GR. Treatment of metastatic Vipoma by liver transplantation. Clin Transplant. 1990 Oct. 4(5 part 1):276-8; discussion 279. [Medline].